Lantern Pharma Inc. reported its financial results for the second quarter of 2025, highlighting a net loss of $4.33 million for the quarter, compared to a net loss of $4.96 million in the same period in 2024. This represents a slight improvement in net loss year-over-year. Research and development expenses for the quarter decreased to $3.1 million from $3.9 million the previous year, reflecting disciplined cost management while advancing clinical programs. General and administrative expenses were stable at approximately $1.6 million compared to $1.5 million in the same quarter of 2024. The company also achieved a major milestone by successfully completing enrollment for the LP-184 Phase 1a clinical trial, with 65 patients enrolled across various solid tumors, including glioblastoma. The maximum tolerated dose and recommended Phase 2 dose for LP-184 were established, which will enable advancement to upcoming Phase 1b/2 trials planned for recurrent triple-negative breast cancer and recurrent bladder cancer. Additionally, a remarkable complete response was observed in a patient from the HARMONIC™ trial with advanced non-small cell lung cancer. Lantern Pharma's anticipated expenditures are expected to fund operating expenses and capital expenditure requirements at least into June 2026.